ZGGS34
/ Suzhou Zelgen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 03, 2025
Study of ZGGS34 in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=400 | Not yet recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial • Solid Tumor
September 18, 2025
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection
(flcube.com)
- "The drug, a trispecific T‑cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor‑associated antigen MUC17, is slated for use in patients with MUC17‑positive advanced solid tumors....Suzhou Zelgen plans to initiate the first‑in‑human Phase II study later this year, enrolling up to 120 MUC17‑positive patients across 10 sites nationwide."
New P2 trial • Solid Tumor
1 to 2
Of
2
Go to page
1